Centanafadine, a novel investigational compound for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults, demonstrated statistically significant improvements compared with placebo in a pair of 6-week, phase 3 clinical trials, announced maker Otsuka Pharmaceutical Co. Ltd. and its US subsidiary Otsuka Pharmaceutical Development & Commercialization, Inc.